Ring Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 47

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $86.5M

  • Investors
  • 10

Ring Therapeutics General Information

Description

Developer of medical gene therapeutics designed to be incorporated through a novel viral vector platform. The company's platform aims to expand the applications of DNA-based treatments beyond gene replacement while targeting sites of disease with cellular and tissue specificity including genetic disorders, ophthalmology, oncology, and metabolic disorders among others, enabling healthcare companies to provide therapeutics as per the specific diseases using a much wider array of modalities and mechanisms.

Contact Information

Website
www.ringtx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 620 Memorial Drive
  • Suite 300
  • Cambridge, MA 02141
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 620 Memorial Drive
  • Suite 300
  • Cambridge, MA 02141
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ring Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 09-Mar-2023 $86.5M Completed Generating Revenue
3. Early Stage VC (Series B) 28-Jul-2021 Completed Generating Revenue
2. Early Stage VC (Series A) 10-Dec-2019 $50M $50M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Ring Therapeutics’s complete valuation and funding history, request access »

Ring Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A1 7,063,260 $0.001000 $2 $2 1x $2 10.8%
Series A 11,017,231 $0.001000 $1 $1 1x $1 16.85%
To view Ring Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Ring Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medical gene therapeutics designed to be incorporated through a novel viral vector platform. The company's
Drug Discovery
Cambridge, MA
47 As of 2026

Brisbane, CA
 

Barcelona, Spain
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ring Therapeutics Competitors (45)

One of Ring Therapeutics’s 45 competitors is Annexon Biosciences, a Formerly VC-backed company based in Brisbane, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Annexon Biosciences Formerly VC-backed Brisbane, CA
Minoryx Venture Capital-Backed Barcelona, Spain
Kriya Therapeutics Venture Capital-Backed Morrisville, NC
Prevail Therapeutics Formerly VC-backed New York, NY
Sana Biotechnology Formerly VC-backed Seattle, WA
You’re viewing 5 of 45 competitors. Get the full list »

Ring Therapeutics Patents

Ring Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230227849-A1 Methods of identifying and characterizing anelloviruses and uses thereof Pending 17-Jun-2020
US-11166996-B2 Anellovirus compositions and methods of use Active 12-Dec-2018
US-11446344-B1 Anellovirus compositions and methods of use Active 12-Dec-2018
US-20200188456-A1 Anellovirus compositions and methods of use Active 12-Dec-2018
US-20220362315-A1 Anellovirus compositions and methods of use Inactive 12-Dec-2018 C12N15/111
To view Ring Therapeutics’s complete patent history, request access »

Ring Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ring Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
CJ Investment Corporate Venture Capital Minority
Kyowa Kirin Corporation Minority
Altitude Life Science Ventures Venture Capital Minority
Invus (Private Equity) PE/Buyout Minority
You’re viewing 5 of 10 investors. Get the full list »

Ring Therapeutics FAQs

  • When was Ring Therapeutics founded?

    Ring Therapeutics was founded in 2017.

  • Where is Ring Therapeutics headquartered?

    Ring Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Ring Therapeutics?

    Ring Therapeutics has 47 total employees.

  • What industry is Ring Therapeutics in?

    Ring Therapeutics’s primary industry is Drug Discovery.

  • Is Ring Therapeutics a private or public company?

    Ring Therapeutics is a Private company.

  • What is the current valuation of Ring Therapeutics?

    The current valuation of Ring Therapeutics is .

  • What is Ring Therapeutics’s current revenue?

    The current revenue for Ring Therapeutics is .

  • How much funding has Ring Therapeutics raised over time?

    Ring Therapeutics has raised $254M.

  • Who are Ring Therapeutics’s investors?

    Alexandria Venture Investments, CJ Investment, Kyowa Kirin, Altitude Life Science Ventures, and Invus (Private Equity) are 5 of 10 investors who have invested in Ring Therapeutics.

  • Who are Ring Therapeutics’s competitors?

    Annexon Biosciences, Minoryx, Kriya Therapeutics, Prevail Therapeutics, and Sana Biotechnology are some of the 45 competitors of Ring Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process